

Title: **EP0722731B1: REMEDY FOR SPINOCEREBELLAR DEGENERATION**[German][French]

Derwent Title: Agent for treating spino-cerebellar degeneration - esp. Machado-Joseph disease, is pterin deriv. esp. tetra:hydro-biopterin [Derwent Record]

Country: EP European Patent Office (EPO)

Kind: **B1** Patent [i] (See also: EP0722731A1, EP0722731A4)

Inventor: **SAKAI, Tetsuo;**
ANTOKU, Yasunobu;
MATSUISHI, Toyojiro;

Assignee: **SUNTORY LIMITED**
Corporate Tree data: Suntory Ltd. (SUNTORY);
News, Profiles, Stocks and More about this company

Published / Filed: **2002-06-05** / 1995-08-04

Application Number: **EP1995000927966**

IPC Code: Advanced: C07D 475/04;
Core: C07D 475/00;
IPC-7: A61K 31/505;
C07D 475/04;

ECLA Code: **C07D475/04;**

Priority Number: 1994-08-05 **JP1994000184682**

Abstract: [From equivalent EP0722731A1] A remedy for spinocerebellar degeneration containing a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as the active ingredient, wherein R1 and R2 represent each hydrogen or they are combined together to represent a single bond; and R3 represents -CH(OH)CH(CH)CH3, -CH(OCOCH3)CH(OCOCH3)CH3, -CH3, -CH2OH or phenyl when R1 and R2 represent each hydrogen, while R3 represents -COCH (OH)CH3 when R1 and R2 together represent a single bond. [French]

Attorney, Agent or Firm: **Hansen, Bernd, Dr. Dipl.-Chem. ;**

INPADOC Legal Status: Show legal status actions Get Now: Family Legal Status Report

Designated Country: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

Family:

PDF	Publication	Pub. Date	Filed	Title
	WO9603989A1	1996-02-15	1995-08-04	REMEDY FOR SPINOCEREBELLAR DEGENERATION
	US5753656	1998-05-19	1995-08-04	Method for treating spinocerebellar degeneration
	JP02761104B2	1998-06-04	1995-08-04	SEKIZUISHONOHENSEISHOCHIRYOZAI
	ES2177654T3	2002-12-16	1995-08-04	REMEDIO CONTRA LA DEGENERACION ESPINOCEREBE
	EP0722731B1	2002-06-05	1995-08-04	REMEDY FOR SPINOCEREBELLAR DEGENERATION
	EP0722731A4	1998-03-04	1995-08-04	REMEDY FOR SPINOCEREBELLAR DEGENERATION
	EP0722731A1	1996-07-24	1995-08-04	REMEDY FOR SPINOCEREBELLAR DEGENERATION

☑	DE69526918T2	2002-12-19	1995-08-04	ARZNEIMITTEL GEGEN SPINOCEREBELLARE DEGENER/
	DE69526918C0	2002-07-11	1995-08-04	ARZNEIMITTEL GEGEN SPINOCEREBELLARE DEGENER/
☑	AT0218345E	2002-06-15	1995-08-04	ARZNEIMITTEL GEGEN SPINOCEREBELLARE DEGENER/
10 family members shown above				

First Claim:
Show all claims

1. The use of a compound represented by the formula: wherein R^1 and R^2 each represents a hydrogen atom or, together, represent a single bond while R^3 represents $-CH(OH)CH(OH)CH_3$, $-CH(OCOCH_3)CH(OCOCH_3)CH_3$, $-CH_3$, $-CH_2OH$ or a phenyl group when R^1 and R^2 each represents a hydrogen atom, or $-COCH(OH)CH_3$ when R^1 and R^2 together represent a single bond or its salt for the preparation of a medicament useful for the treatment of spinocerebellar degeneration.
[German] [French]

Description
Expand description

± Background of the Invention
± Field of Application in Industry

The present invention relates to the use of an agent for treating spinocerebellar degeneration containing as an effective ingredient a compound represented by the formula (I): wherein R^1 and R^2 each represents a hydrogen atom or, together, represent a single bond while R^3 represents $-CH(OH)CH(OH)CH_3$, $-CH(OCOCH_3)CH(OCOCH_3)CH_3$, $-CH_3$, $-CH_2OH$ or a phenyl group when R^1 and R^2 each represents a hydrogen atom, or $-COCH(OH)CH_3$ when R^1 and R^2 together represent a single bond
or its pharmaceutically acceptable salt.

± Prior Art
± Summary of the Invention
± Detailed Description of the Invention
± Examples
± Example 1 (Granules and fine granules)
± Example 2 (Tablets)
± Example 3 (Capsules)
± Example 4 (Injection)
± Example 5 (Injection)
± Example 6 (Suppositories)
± Example 7 (Granules)
± Example 8 (Granules)
± Example 9 (Granules)
± (Preliminary study)
± 1. Clinical study:
± 2. Biochemical study to clarify the mechanisms of pharmacological actions
± (1) Before treatment with S-T preparation:
± (2) After treatment with S-T preparation.
± (Therapeutic Example)
± <Subjects and Methods>
± 1. Subjects
± 2. Treatment period
± 3. Dosage
± 4. Evaluation methods
± a. Subjective improvement
± b. Neurological examination
± c. Timed tests
± 5. Study design
± 6. Statistical analysis
± <Results>
± 1. Subjective symptoms
± 2. Objective findings
± (1) Neurological checkup
± (2) Timed tests
± <Conclusion>

Other Abstract Info: CHEMABS 124(26)352702J DERABS C1996-129111